phospho-FADD (Ser194) Rabbit pAb
phospho-FADD (Ser194) Rabbit pAb
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application ![]()
| IHC-P, IHC-F, IF |
---|---|
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Calculated MW | 23 KDa |
Physical State | Liquid |
Immunogen | KLH conjugated Synthesised phosphopeptide derived from human FADD around the phosphorylation site of Ser194 |
Epitope Specificity | AM(p-S)PM |
Isotype | IgG |
Purity | affinity purified by Protein A |
Buffer | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
SIMILARITY | Contains 1 death domain. Contains 1 DED (death effector) domain. |
SUBUNIT | Can self-associate. Interacts with CFLAR, PEA15 and MBD4. When phosphorylated, part of a complex containing HIPK3 and FAS. May interact with MAVS/IPS1. Interacts with MOCV v-CFLAR protein and LRDD. Interacts (via death domain) with FAS (via death domain). Interacts with CASP8. |
DISEASE | The interaction between the FAS and FADD death domains is crucial for the formation of the death-inducing signaling complex (DISC). Defects in FADD are the cause of infections recurrent associated with encephalopathy hepatic dysfunction and cardiovascular malformations (IEHDCM) [MIM:613759]. A condition with biological features of autoimmune lymphoproliferative syndrome such as high-circulating CD4(-)CD8(-)TCR-alpha-beta(+) T-cell counts, and elevated IL10 and FASL levels. Affected individuals suffer from recurrent, stereotypical episodes of fever, encephalopathy, and mild liver dysfunction sometimes accompanied by generalized seizures. The episodes can be triggered by varicella zoster virus (VZV), measles mumps rubella (MMR) attenuated vaccine, parainfluenza virus, and Epstein-Barr virus (EBV). |
Important Note | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
Background Descriptions | Predicted to enable several functions, including caspase binding activity; death effector domain binding activity; and tumor necrosis factor receptor superfamily binding activity. Involved in several processes, including hematopoietic or lymphoid organ development; negative regulation of activation-induced cell death of T cells; and positive regulation of CD8-positive, alpha-beta cytotoxic T cell extravasation. Acts upstream of or within extrinsic apoptotic signaling pathway in absence of ligand; motor neuron apoptotic process; and regulation of programmed cell death. Predicted to be located in several cellular components, including cell body; cytosol; and membrane raft. Predicted to be part of CD95 death-inducing signaling complex and ripoptosome. Predicted to be active in cytoplasm. Is expressed in several structures, including alimentary system; brain; genitourinary system; hemolymphoid system gland; and liver and biliary system. Human ortholog(s) of this gene implicated in leukemia. Orthologous to human FADD (Fas associated via death domain). [provided by Alliance of Genome Resources, Apr 2022] |
Target/Specificity | Expressed in a wide variety of tissues, except for peripheral blood mononuclear leukocytes. |
---|---|
Dilution | IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500 |
Format | 0.01M TBS(pH7.4), 0.09% (W/V) sodium azide and 50% Glyce |
Storage | Store at -20 ℃ for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 ℃. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.